Tel.:
+34 91 736 2385
LOCAL TIME
Contact:
Katarina Gluic
Hours:
Mon-Thu 8:30-17:00 Fri 8:30-15:00
05:01
For help with a poster, please specify the poster number, the first author and the congress and we will reply shortly.
Poster no.
Contact name
E-mail
Telephone
Congress
Comments
WFH 2014 World Congress
11-15 May 2014 Melbourne
About us
FAQs
Help Line
Personal Area
Homepage
Discussion forum -
WFH 2014 World Congress
Topic -
Clinical Issues and Trials
If you are already registered in PosterSessionOnline, enter your e-mail and click on LOGIN. Otherwise click on REGISTER
Thread / Poster
Author
Replies
Last reply
Global Development Plan for a Double Virus Inactivated Fibrinogen Concentrate for the Treatment of Congenital Fibrinogen Deficiency
Anna Klukowska
1
5/5/2014 6:01:00 PM
Individualized prophylaxis with Human-cl rhFVIII in adult patients with severe haemophilia A
Anna Klukowska
1
5/5/2014 5:58:00 PM
A Clinical Study In Previously Untreated Patients With Severe Haemophilia A - Immunogenicity, Efficacy and Safety Of Treatment With Human-cl rhFVIII
Anna Klukowska
1
5/5/2014 5:54:00 PM
Latest Results From The PUP-GCP Clinical Trial: A Low Inhibitor Rate In Previously Untreated Patients With Severe Hemophilia A Treated With Octanate
Anna Klukowska
1
5/5/2014 5:45:00 PM
EpiNine interim analysis of a non-interventional, multicentre study in patients with haemophilia B
Christoph Koenigs
1
5/2/2014 2:14:00 PM
Safety and effectiveness of anti inhibitor coagulation complex (AICC) in routine clinical management: a post-authorization safety study (PASS)
Aaron Novack
1
4/23/2014 11:26:00 PM
Safety Profile of IB1001, Recombinant Factor IX (trenonacog alfa) in the Treatment of Hemophilia B
Hugo Astacio
1
4/23/2014 8:22:00 PM
Real-life clinical experience of 117 previously untreated patients (PUPs) treated with antihemophilic factor (recombinant), plasma/albumin free method in Japanese post authorization safety surveillance
Masashi Taki
1
4/23/2014 2:41:00 PM
The Results of Clinical Trial Evaluating of the Efficacy and Safety of Octofactor compared Octanate in the Treatment of Bleeding in Patients with Severe and Moderate Hemophilia A
Nina Klimova
1
4/23/2014 1:03:00 PM
What we learn from data of a prospective post-authorization safety surveillance study in 384 hemophilia A patients with antihemophilic factor (recombinant) plasma / albumin free method demonstrates safety and efficacy in Japan
KATSUYUKI FUKUTAKE
1
4/23/2014 11:32:00 AM
PHARMACOKINETIC PROPERTIES, SAFETY AND TOLERABILITY OF NEW B-DOMAIN DELETED RECOMBINANT FACTOR VIII (OCTOFACTOR) IN PATIENTS WITH SEVERE AND MODERATELY SEVERE HEMOPHILIA A
Vladimir Zorenko
1
4/10/2014 2:27:00 PM
Most viewed poster for this congress
Poster:
1
Visits:
2526
Title:
A WEB SITE TO IMPROVE MANAGEMENT OF PATIENTS WITH INHERITED BLEEDING DISORDERS IN THE EMERGENCY DEPARTMENT: RESULTS AT 2 YEARS
Authors:
Annarita Tagliaferri ,
Centre:
Centro di Riferimento Regionale per la cura dellEmofilia
Poster most viewed in this topic
Poster:
43
Visits:
280
Title:
A Clinical Study In Previously Untreated Patients With Severe Haemophilia A - Immunogenicity, Efficacy and Safety Of Treatment With Human-cl rhFVIII
Authors:
Raina Liesner , M Jansen, S Knaub
Centre:
Octapharma Clinical R&D
About us
Terms and Conditions
Special Access
Commercial Web Access
Follow us on: